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Infectious bovine rhinotracheitis is caused by BHV-1 and is clinically characterized by hyperemia and hy-
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Objective—To assess long-term effects and risk factors for the efficacy of hyperimmuniza-
tion protocols against infectious bovine rhinotracheitis (IBR) during a longitudinal field study 
of dairy and dairy-beef mixed farms.
Animals—Approximately 7,700 cows from 72 farms.
Procedures—Farms were assigned to 3 treatment groups (hyperimmunization groups 
[HIGs] 1 and 2, which were hyperimmunized with glycoprotein E [gE]–deleted marker vac-
cines, and a nonintervention group [NIG]). Cattle in HIG 1 were initially vaccinated with an 
attenuated vaccine, whereas cattle in HIG 2 were initially vaccinated with an inactivated-
virus vaccine. Cattle in both HIGs received booster inoculations with inactivated-virus vac-
cines at 6-month intervals. The risk for gE seroconversion was compared among experi-
mental groups via a shared frailty model with a piecewise constant baseline risk to correct 
for seasonal and secular effects.
Results—Risk for gE seroconversion significantly decreased over time for the HIGs, com-
pared with the NIG. Seasonal changes in the risk of gE seroconversion were detected, with 
a higher risk during winter periods, compared with grazing periods. No significant differ-
ence was detected between HIGs 1 and 2. The only significant risk factor was the number 
of buildings for cattle on a farm; the higher the number of buildings, the lower the risk for 
gE seroconversion. Prevalence of IBR decreased over time in both HIGs but remained con-
stant or increased in the NIG.
Conclusions and Clinical Relevance—Hyperimmunization via repeated administration of 
attenuated and inactivated-virus gE-deleted marker vaccines as well as inactivated-virus 
vaccines may provide a method for control of IBR. (Am J Vet Res 2012;73:1787–1793)
persecretion of the nasal mucosa, cough, and fever. 
Bovine herpesvirus-1 is also the causative agent of re-
productive tract problems, such as infectious vulvo-
vaginitis, abortions, and metritis after cesarean section. 
The worldwide distribution of BHV-1 makes it a major 
pathogen of cattle.1
Because it is an alphaherpesvirus, BHV-1 remains 
in the nervous system after infection in cattle and can 
be reactivated by stressful conditions.2 The frequency 
and intensity of viral shedding after reactivation are in-
fluenced by the strain virulence and the immune status 
of the animal.3 In countries (eg, Belgium4 and the Neth-
erlands5) where the seroprevalence for IBR is high, the 
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control strategy is based on repeated vaccination of all 
cattle in a herd. For the past 15 years, marker vaccines6,7 
have allowed for the serologic discrimination between 
cattle infected with BHV-1 (seropositive against gE) and 
vaccinated cattle (seronegative against gE).8
Two field studies9,10 have been conducted over a 
period of 1 year to assess efficacy for the repeated ad-
ministration of gE-deleted marker vaccine to cattle in 
dairy herds. Both compared results for repeated vacci-
nation with results for placebo treatments. The authors 
concluded that the repeated use of live-virus9 or inacti-
vated-virus10 vaccines reduces the incidence of gE sero-
conversion. Vaccination with a live-attenuated strain of 
virus resulted in a smaller reproductive ratio9 and was 
used to control IBR in the Netherlands. This strategy 
was later rejected because of vaccine contamination.11 
More recently, hyperimmunization protocols that in-
volve the use of live-virus vaccines have been success-
fully tested in 149 herds, mostly large dairy farms.12
Although a hyperimmunization protocol that in-
volves the use of sequential administration of live-virus 
and inactivated-virus vaccines was found to be effi-
cient,13 it has not been tested in farm settings. Current-
ly, putative risk factors for BHV-1 infection have been 
estimated via cross-sectional observational studies.5,14 
Only randomized studies are able to determine that a 
risk factor is causative for the studied disease.
For the analysis of the study reported here, a new 
model for survival analysis was developed. The model 
was designed to take into account modification of the 
intensity of risk factors with time, clustering of animals 
in a herd, seasonal differences, and long-term change 
in risk over time (secular change). The objective of the 
study reported here was to assess in farm settings for a 
28-month period the risk factors for BHV-1 infection 
in cattle herds hyperimmunized in accordance with 2 
hyperimmunization protocols and compare them with 
those for herds without such interventions. We hypoth-
esized that the infection rate in an HIG would decrease 
over time, compared with that for the NIG.
Materials and Methods
Animals—The study was conducted with cattle 
from 34 dairy herds and 38 dairy-beef mixed herds that 
were selected from a pool of 92 volunteer herds. Inclu-
sion criteria for the herds were that farming activity was 
the only source of family income and that a herd com-
prised ≤ 180 cattle.
Procedures—Farms were assigned to 3 groups (HIG 1, 
HIG 2, and NIG) by use of a randomization procedure 
(lottery procedure). All of the cattle in HIG 1 and 2 were 
hyperimmunized. This consisted of an initial 2 adminis-
trations of marker vaccines (interval of 3 to 5 weeks be-
tween administrations), which were followed by booster 
vaccinations at intervals of approximately 6 months. To 
ensure identification of the treated cattle, vaccinations 
were performed at the start of the study (January 1997) 
and then successively shortly before the start of the cattle 
pasture periods and as soon as possible after the start of 
the cattle stabling periods for a period of 28 months.
Cattle in HIG 1 initially received 2 intranasal ad-
ministrations of an attenuated gE-deleted marker 
vaccine.a,b Cattle in HIG 2 initially received 2 SC ad-
ministrations of an inactivated-virus gE-deleted mark-
er vaccine.c,d Both hyperimmunized groups received 
booster inoculations of the inactivated-virus vaccines,c,d 
SC, at 6-month intervals. For the NIG, farmers used 
their usual vaccination schedules. All cattle of appro-
priate age for vaccination in each herd were included in 
the study. Only gE-deleted marker vaccines were used 
for all 3 groups, which allowed for serologic differen-
tiation between infected and uninfected but vaccinated 
cattle.8
Serologic monitoring—To limit the amount of ani-
mal handling, serologic monitoring of all cattle was con-
ducted via the same schedule as the vaccinations, which 
provided 6 cross-sectional blood sample collections of the 
72 herds. Each blood sample was tested with an ELISA 
gE antibody test kit.e Inconclusive results were considered 
as positive.15 Whenever possible, the serologic status of 
calves that had positive results because of maternal anti- 
bodies was adjusted to that of the first test value obtained 
after those calves were 6 months old. In all other cases, 
cattle that had at least 1 positive test result were defini-
tively considered as latent carriers and positive cattle 
for subsequent measurements. Calves < 6 months old 
for which no subsequent sample was available were ex-
cluded because there was no further analysis to define 
their immune status. New cases of BHV-1 infection were 
defined as gE seroconversion during the interval since 
the preceding sampling period.
Questionnaire for the risk factor analysis—Each 
owner completed a questionnaire about the herd man-
agement practices potentially linked to the risk of BHV-1 
infection; the questionnaire was completed during a 
face-to-face interview. The questionnaire was designed 
on the basis of results for studies14,16 of within-herd and 
between-herd risk factors and considered potential risk 
factors linked with herd management (ie, regular pur-
chase of cattle, participation at fairs and shows, calf-
dam relationship [whether calf was removed immedi-
ately after birth], use of artificial insemination or natu-
ral mating with bulls, and external sources of infection 
[ie, the presence of other farms within a radius of 100 m 
and possible contacts with other herds during the pas-
ture period]).
Descriptive epidemiology—Six blood collections 
were performed for each herd during the study. For 
each sample collection, seroprevalence was estimated 
as the ratio of the number of gE-seropositive cattle to 
the number of cattle from which blood samples were 
collected.
Data analysis—Data analysis was conducted to ac-
count for cattle lost to follow-up monitoring, clustering 
of data collected at the same farm (all cattle in a herd 
were managed in the same manner [random effect]), 
season (animal density differed between winter [sta-
bling period] and summer [grazing period]), natural 
turnover of cattle (birth of calves and purchase of cattle 
were balanced against death, culling, and sale of cattle, 
which resulted in a continuous entrance of cattle into 
and exit of cattle from the study population), and long-
term change of the risk ratio over time.
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A survival model is the most appropriate technique 
to use for analysis of time-to-event data (eg, time to 
seroconversion). The expected seasonal effect was cor-
rected by assuming 2 seasons/y (ie, summer and win-
ter), each of which had a different constant baseline 
risk. This simple model was extended with a random 
effect for each farm, u
i
. The shared frailty was assumed 
to follow a 1-parameter gamma-distribution with a 
mean of 1 and variance of θ. This meant that an aver-
age frailty (u
i
 equal to 1) had no effect on the risk for 
seroconversion. This resulted in a piecewise constant 
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, … are 
the baseline risks for period 1, 2, …; I is the indicator 
function, which is 1 if the condition is true and 0 if the 
condition is false; 153, 335, … are the boundaries of the 
seasons in number of days; exp(α) is the difference in 
risk at the start of the study between the HIGs and the 
NIG; and β is the effect of an HIG over time. The base-
line risk for each group was the baseline risk of the NIG 
multiplied by exp(α). The differences at the start of the 
study were not expected to be significant.
Comparison of the time to seroconversion of the HIG 
cattle with that of the NIG was used to establish the secu-
lar change in the time to seroconversion since the start of 
the hyperimmunization protocol on a farm. This implied 
that most cattle entered the study at a time different from 
0. Only the period starting at the entrance of an animal 
(yij0) until an event or censoring time (yij) may have an 
effect on the cumulative risk. Therefore, the risk function 
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The β values for HIG 1 and HIG 2 were an indica-
tion of the change in the risk over time. However, if 
Blood
sample No.† HIG 1 HIG 2 NIG
      1 2,140 (20) 2,379 (20) 3,387 (32)
      2 2,194 (20) 2,449 (20) 3,337 (32)
      3 2,169 (20) 2,383 (20) 3,284 (32)
      4 2,152 (20) 2,211 (20) 3,208 (32)
      5 2,086 (20) 2,278 (20) 3,162 (32)
      6 1,688 (19) 1,797 (19) 1,718 (20)
 
*Cattle in HIG 1 were initially vaccinated with 2 doses of an at-
tenuated vaccine, whereas cattle in HIG 2 were initially vaccinated 
with 2 doses of an inactivated-virus vaccine. Then, cattle in both 
HIGs received booster inoculations with inactivated-virus vaccines 
at approximately 6-month intervals. For the NIG, farmers used their 
usual vaccination schedules. Only gE-deleted marker vaccines 
were used for all 3 groups. †To minimize cattle handling, blood 
samples were collected at the time of initial vaccinations (January 
1997) and then at approximately 6-month intervals to coincide with 
2 seasons (winter with stabling conditions and summer with grazing 
conditions).
Table 1—Number of cattle (No. of herds) in each of 3 experimen-
tal groups* that were tested for gE seroconversion at 6 succes-
sive blood sample collections.
Figure 1—Change in the mean gE seroprevalence of cattle in 3 
experimental groups (HIG 1 [thin black line], HIG 2 [thick gray 
line], and NIG [dashed gray line]) as determined at each of 6 blood 
sample collections for dairy herds (A), female cattle of dairy-beef 
mixed herds (B), and male cattle of dairy-beef mixed herds (C). 
Cattle in HIG 1 were initially vaccinated with 2 doses of an attenu-
ated vaccine, whereas cattle in HIG 2 were initially vaccinated 
with 2 doses of an inactivated-virus vaccine. Then, cattle in both 
HIGs received booster inoculations with inactivated-virus vac-
cines at approximately 6-month intervals. For the NIG, farmers 
used their usual vaccination schedules. Only gE-deleted marker 
vaccines were used for all 3 groups, To minimize cattle handling, 
blood samples were collected at the time of vaccinations (approx 
6-month intervals).
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hyperimmunization were to reduce the number of new 
infections, then a secular reduction (a negative β value 
for HIG 1 and HIG 2) in the risk for seroconversion 
would be expected. 
Risk factors related to management practices that 
were obtained from the questionnaire were also intro-
duced into the model as additional covariates. A for-
ward-stepwise selection procedure was used to build 
the final model. Only risk factors with a value of P < 
0.1 were considered for the stepwise procedure to build 
the final model. The corresponding survival function 
was then described by the following equation:
S
ij
(t) = exp ([λ
1
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2








(t) is the survival function at time t. By use 
of these equations, the marginal likelihood for the ith 
cluster was calculated as follows:
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(λ, α, β, θ) is the marginal likelihood for the 
ith cluster, H
0
 is the cumulative baseline risk, and δ
ij
 
is the censor indicator (1 in case of an event and 0 in 
case of right censoring). The variance of the frailties 
(θ) may be interpreted as an indication of 
the differences among the farms (ie, the 
higher the variance, the greater the dif-
ferences among the farms). Alternatively, 
after conversion to Kendall τ (estimated 
as θ/[θ + 2]), the variance may be con-
sidered as a measure for the intraclass 
correlation.17
Separate models were fitted for dairy 
herds and dairy-beef mixed herds. Be-
cause females and males were housed in 
separate buildings and had different pop-
ulation turnover and contact structure, 
differences in their risk ratio for sero-
conversion could be assumed. Therefore, 
separate analyses were also performed for 
each sex population of the mixed herds, 
following the same forward-stepwise selection of risk 
factors. For all final models, values of P < 0.05 were 
considered significant.
Results
Animals—One farmer in HIG 1 and another in 
HIG 2 opted to leave the study before the last win-
ter period because they considered the schedule for 
collection of blood samples to be excessively restric-
tive. In the NIG, 12 farmers left the study during the 
last period because they wanted to start a hyperim-
munization program or were excluded because they 
wanted to modify the main type of production for 
their farm. Thus, at the end of the study, there were 
19, 19, and 20 herds remaining in HIG 1, HIG 2, and 
the NIG, respectively (Table 1).
Dairy herds—Although the farms were ran-
domly allocated to the various experimental groups, 
the mean seroprevalence at the start of the study was 
higher for HIG 1 (45%) than for HIG 2 (33%) and 
the NIG (35%; Figure 1). The gE seroprevalence 
decreased systematically in both hyperimmunized 
groups during the first 4 periods but remained al-
most constant in the NIG. During the last period, 
the gE seroprevalence increased slightly in HIG 1, 
remained constant in HIG 2, and markedly increased 
in the NIG.
The estimated risks of gE seroconversion over time 
were calculated (Figure 2). At the start of the study, the 
baseline risks were not significantly different for HIG 1 
and HIG 2, compared with that for the NIG (α values 
for HIG 1 and HIG 2 were not significantly different 
from 0; Table 2). The risk ratio for gE seroconversion 
was higher for the NIG than for HIG 1 or HIG 2. In 
addition, increased protection with time was observed 
for both HIG 1 and HIG 2, as indicated by a change in 
the risk over time in HIG 1 and HIG 2, compared with 
that for the NIG (β values for HIG 1 and HIG 2 were 
negative and significantly different from 0). Although 
the reduction over time was slightly greater for HIG 2 
than for HIG 1, there was no significant difference in 
the risk ratio for gE seroconversion over time between 
the 2 HIGs.
The decreasing risk was also evident by the change 
in the mean seroprevalence on a herd-level basis (Fig-
Coefficient Estimate P value†
θ 1.563 (0.396) < 0.001
α  
  HIG 1 –0.148 (0.566) 0.793
  HIG 2 –0.568 (0.627) 0.365
β  
  HIG 1 –0.734 (0.174) < 0.001
  HIG 2 –0.761 (0.197) < 0.001
  Building‡ –0.471 (0.182) 0.010
†Values were considered significant at P < 0.05. ‡Effect of an 
additional building for cattle on a farm.
α = Initial difference between the HIG and the NIG. β = Change 
over time attributable to the HIG. θ = Variance among farms.
See Table 1 for remainder of key.
Table 2—Estimate (SE) for the coefficients of the piecewise 
constant risk model for dairy cows in 3 experimental groups.* 
Figure 2—Change in the risk ratio for gE seroconversion over time in dairy herds 
for HIG 1, HIG 2, and the NIG. Winter periods with stabled conditions (shaded 
areas) and summer conditions with grazing conditions (unshaded areas) are indi-
cated. The initial 2-dose vaccinations were administered at time 0. See Figure 1 
for remainder of key.
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ure 1). The seroprevalence in the HIGs primarily had 
a pattern of decreasing values, whereas the seropreva-
lence for the NIG remained almost constant.
Seasonal differences were determined by use of the 
risk for seroconversion for the NIG as the baseline value. 
The winter periods were always associated with a higher 
baseline risk than were the summer periods (Figure 2). 
The estimated θ was 1.563 (Table 2). This corre-
sponded to a Kendall τ of 0.439, which indicated a high 
correlation within the herds. 
After consideration of all available risk factors, the 
final model revealed that only the number of buildings 
for cattle on a farm had an additional significant effect 
on the risk ratio. The greater the number of buildings 
on a farm, the lower the risk for gE seroconversion (risk 
ratio, 0.62/building).
Dairy-beef mixed herds—Although the farms 
were randomly allocated among the various experi-
mental groups, the mean seroprevalence at the start of 
the study for the female population was lower for the 
NIG (36%) than for HIG 1 (56%) and HIG 2 (46%; 
Figure 1). In females, the baseline risk for seroconver-
sion was significantly higher for the HIGs than for the 
NIG (α values for HIG 1 and HIG 2 were significantly 
> 0; Table 3). There was no significant difference in the 
baseline risk for gE seroconversion between HIG 1 and 
HIG 2. Over time, HIG 1 and HIG 2 had a large and 
significantly lower risk for seroconversion, compared 
with the risk for seroconversion for the NIG (β values 
for HIG 1 and HIG 2 were significantly < 0), which 
indicated that the protection conferred by hyperimmu-
nization increased over time and was twice as large as 
the value for dairy cattle.
In the male population, there were no significant 
differences between the 2 HIGs and the NIG at the start 
of the study or over time. Also, seasonal differences 
were less pronounced in the male popula-
tion, compared with seasonal differences in 
female cattle of beef-dairy mixed herds and 
for the dairy herds (Figure 3).
Clustering had an important effect 
on the model, which indicated that herd 
management practices and environmen-
tal factors can have a major impact on the 
control of IBR. For female cattle in dairy-
beef mixed herds, a value of 1.501 was 
estimated for θ (Kendall τ, 0.429), which 
was similar to the values for the dairy 
herds. However, the estimated θ in beef 
bulls was 2.761, which was much higher 
than that of the female cattle and resulted 
in an extremely high intraclass correlation 
(0.580). 
All risk factors were considered for the 
final model of female and male cattle of the 
dairy-beef mixed herds. However, none of 
them had a significant effect on the risk ra-
tio for gE seroconversion.
Discussion
The randomized longitudinal study re-
ported here was based on the individual gE serologic 
follow-up monitoring of all cattle in 3 experimental 
groups on dairy and dairy-beef mixed farms. Two hy-
perimmunization protocols were used, and both sig-
nificantly reduced the risk of BHV-1 infection in the 
females, compared with the risk for the NIG. However, 
it was not possible to detect the same effect in the male 
population of the dairy-beef mixed herds. These results 
are consistent with those obtained in previous field 
studies that revealed a reduction of virus circulation in 
cattle herds hyperimmunized with live-virus vaccine9,12 
or an inactivated-virus vaccine.10 
It is not possible to make further comparisons be-
tween results of other studies and those of the present 
study because conclusions of other studies were based 
on the reproduction ratio18 calculated for a period of 18 
months in studies in which only female cattle > 1 year 
old were included. By comparison, the present study 
was based on an analysis of the time to seroconversion 
in all cattle on the farms measured over shorter inter-
vals and for a much longer period (28 months). In con-
trast to the calculation of the reproduction ratio, the 
proposed piecewise constant risk model estimates the 
Figure 3—Change in the risk ratio for gE seroconversion over time in dairy-beef 
mixed herds for HIG 1, HIG 2, and the NIG for females (A) and males (B). See 
Figures 1 and 2 for remainder of key.
Table 3—Estimate (SE) for the coefficients of the piecewise con-
stant risk model for cattle in 3 experimental groups* for dairy-
beef mixed herds stratified on the basis of sex.
 Females Males
Coefficient Estimate (SE) P value† Estimate (SE) P value†
θ 1.501 (0.336) < 0.001 2.761 (0.946) 0.004
α    
  HIG 1 2.141 (0.570) < 0.001 0.492 (0.928) 0.596
  HIG 2 1.385 (0.521) 0.008 –0.108 (0.783) 0.890
β    
  HIG 1 –1.500 (0.189) < 0.001 0.020 (0.414) 0.961
  HIG 2 –1.572 (0.184) < 0.001 –0.639 (0.428) 0.135
See Tables 1 and 2 for key.
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change in seroprevalence over time and takes into ac-
count clustering, different levels of risk over time, sea-
sonal effects, and the development of herd immunity. 
This results in more information about the behavior of 
the infection, immunity on a herd-level basis, and dif-
ferences between herds than does only a single sum-
mary measure such as the reproductive ratio.
Selection of the 2 hyperimmunization protocols 
was based on results of previous studies. The protocol 
for HIG 1 was based on the conclusions of an experi-
mental trial13 that revealed successive administration 
of live-virus and inactivated-virus vaccines induced 
the production of antibodies and a cellular immune 
response, which were significantly higher than those 
obtained with only a single administration. The pro-
tocol for HIG 2 was based on the administration of 
an inactivated-virus vaccine, which had already been 
tested in a field setting, but for a shorter period.10 Both 
protocols were designed to prevent the development of 
major problems linked with the intensive use of live-
attenuated virus vaccines. These problems include con-
tamination of the vaccine by another virus, reactivation 
or re-excretion of a gE-negative vaccine strain in a field 
setting,19 and potential emergence of highly pathogenic 
gE-negative mutant strains of BHV-120 as a result of re-
combination between vaccine and field strains.
An NIG, rather than a placebo treatment, was used 
in the present study, even though it is more difficult 
to detect a significant difference between control and 
treatment groups. A placebo treatment was not accept-
able because of the increased risk of virus circulation and 
infection, in comparison to the risk for the usual manage-
ment procedures. In addition, it is unethical to force farm-
ers to stop vaccinating cattle (ie, placebo treatment) for 
several years if their animals are selected for the control 
group. Thus, an NIG is commonly used to compare new 
treatments with standard treatments.21,22 
In dairy herds, there were no differences in the ini-
tial risk ratio, but the change over time was significant-
ly < 0 for the HIGs. This resulted in a decrease in risk 
over time for the HIGs, compared with that for the NIG. 
The risk of gE seroconversion for HIG 1 was always 
higher than, or equivalent to, that for HIG 2 (Figure 
2); however, the differences were not significant. This 
observation is in agreement with results of a study10 in 
which animals hyperimmunized with inactivated-virus 
vaccines shed less virus after reactivation than did ani-
mals vaccinated with live-virus vaccine. This suggests 
that the most efficacious approach for the eradication 
of BHV-1 is the use of inactivated-virus vaccines to re-
duce reactivation, as opposed to the administration of 
live-virus vaccines in an attempt to prevent new infec-
tions. This strategy is also supported by results of an-
other study.23
The increased risk for seroconversion during the 
winter periods, which was caused by commingling 
of cattle of various age classes and infection status in 
barns, revealed the limits of hyperimmunization in 
stressful situations. To be effective, hyperimmuniza-
tion has to be applied for a long period (as indicated by 
the significant interaction between time and treatment; 
Tables 2 and 3). Even then, virus circulation cannot be 
totally stopped. Therefore, additional bio-security mea-
sures should accompany the use of hyperimmunization 
protocols. First, adult cows and heifers should receive 
booster inoculations of inactivated-virus gE-deleted 
IBR vaccine at least 15 days before the end of the graz-
ing period. Second, whenever possible during the win-
ter period, gE-seropositive cattle should be separated 
from cattle seronegative for gE. The present study re-
vealed that there was a significant decrease in the risk 
for seroconversion when a farm had more buildings 
for cattle. In addition, as a general rule, calves should 
be immediately removed from their dams, and young 
stock should not have contact with dry (nonlactating) 
cows. This will allow for complete initial vaccination 
and booster administration before contact with a group 
of older animals, which are potential virus shedders. 
The specific accelerated removal of gE-seropositive cat-
tle should be used to decrease the length of the hyper-
immunization schedule. 
In dairy-beef mixed herds, there was a difference 
between the female and male populations. For the fe-
male population, the findings were in agreement with 
those obtained for the dairy herds, although the risk 
ratio for seroconversion was significantly larger in the 
HIGs than in the NIG at the start of the study. This 
is probably attributable to the higher seroprevalence, 
and corresponding infection pressure, at the start of the 
study. 
The risk of gE seroconversion in the HIGs de-
creased over time, compared with that for the NIG, and 
there was no significant difference between the 2 HIGs. 
The decrease over time in the females of the dairy-beef 
mixed herds was faster than that of the dairy herds. The 
higher seroprevalence for the HIGs at the start of the 
study is a possible explanation for this.
For the male population, we did not detect a sig-
nificant difference in the change of the risk for gE sero- 
conversion over time and the seroprevalence among the 
3 groups, which had almost the same pattern. This may 
have been associated with an extremely high turnover rate 
associated with the management of feedlots (grouping of 
stressed cattle without previous testing for IBR and possi-
ble infection before optimal protection from vaccination). 
A reduction in infection pressure can be expected when 
the number of cattle shedding virus decreases among 
older animals as a result of hyperimmunization. In this 
category, a high clustering of infection times at the farm 
level was observed (high θ; Table 3), which resulted in a 
higher correlation within the herds for the male popula-
tion than for the female population. This is indicative of 
large differences among the farms and suggested that the 
management of each farm and environmental factors can 
have a major impact on the control of IBR. 
In the present study, we suggested that hyperim-
munization that involved repeated administration of 
attenuated and inactivated-virus gE-deleted marker 
vaccine (HIG 1) as well as inactivated vaccines (HIG 
2) allowed for the control of IBR. The efficacy of vacci-
nations can be maintained by appropriate management 
during the winter (cold season) and thus shorten the 
time until eradication of IBR.
a. Bayovac IBR-Marker vivum, provided by Bayer AG, Brussels, 
Belgium.
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b. Rhinobovin Marker Live, provided by Intervet Inc, Brussels, 
Belgium.
c. Bayovac IBR-Marker inactivatum, provided by Bayer AG, Brus-
sels, Belgium.
d. Rhinobovin Marker inactivated, Intervet Inc, Brussels, Belgium.
e. HerdCheck, IDEXX, Westbrook, Me.
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